Fig. 2From: Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension studyPain freedom, pain relief, and absence of the most bothersome symptom (MBS) at 2 h after treatment with DFN-11 in the open-label and double-blind study periodsBack to article page